OKYO Pharma Limited – NASDAQ:OKYO

Add to watchlist

$2.33

+1.17

+100.86%

Market open

Closed in about 5 hours

-27.04%

month

-27.04%

quarter

-36.96%

year

Market Cap	36.25M
Enterprise value	N/A

P/E	-2.32
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	34.91
PEG ratio	0.03
EPS	-0.35

Revenue	N/A
EBITDA	-2.26M
Income	-2.25M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

OKYO Pharma Limited (NASDAQ:OKYO): Profit margin
Jun 2021	0	-749.35K
Sep 2021	0	-749.35K
Dec 2021	0	-749.35K
Mar 2023	0	-3.09K

OKYO Pharma Limited (NASDAQ:OKYO): Debt to assets
Jun 2022	1588953	1.89M	119.49%
Sep 2022	1774375	2.12M	119.49%
Dec 2022	4304786	6.00M	139.46%
Mar 2023	5203920	7.25M	139.46%

OKYO Pharma Limited (NASDAQ:OKYO): Cash Flow
Sep 2016	-28	-51	1
Dec 2016	-232	51	-1
Mar 2017	-232	51	-1
Mar 2023	-1.66K	-1	3.03K

OKYO Pharma Limited alternative data

OKYO Pharma Limited (NASDAQ:OKYO): Employee count
Aug 2023	7
Sep 2023	8
Oct 2023	8
Nov 2023	8
Dec 2023	8
Jan 2024	8
Feb 2024	8
Mar 2024	8
Apr 2024	8
May 2024	8
Jun 2024	8
Jul 2024	8

OKYO Pharma Limited
Hedge Funds Holdings Q1 2023

0.00% 0.00%

of OKYO is owned by hedge funds

1 +0

hedge funds hold OKYO stock

19.80K +12.28K

shares is hold by hedge funds

OKYO hedge funds holdings changes

OKYO Pharma Limited
Insider Trading

OKYO Pharma Limited (NASDAQ:OKYO): Insider trades (number of shares)
Period	Buy	Sel
Sep 2023	16670	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	15 Sep 2023	BRANCACCIO JOHN P director director	Ordinary Shares	16,670	$1.5	$25,005
Purchase	19 May 2022	CERRONE GABRIELE M officer: Non-Executive Chairman officer: Non-Executive Chairman	American Depositary Shares	37,500	$4	$150,000
Purchase	19 May 2022	JACOB GARY S officer: Chief Executive Officer officer: Chief Executive Officer	American Depositary Shares	12,500	$4	$50,000
Purchase	19 May 2022	CERRONE GABRIELE M officer: Executive Chairman officer: Executive Chairman	Ordinary Shares	5,800,000	$0.08	$440,800
Purchase	17 May 2022	CERRONE GABRIELE M director, 10 percent owner, officer: No.. director, 10 percent owner, off..	American Depositary Shares	25,000	$3.87	$96,750
Purchase	17 May 2022	CERRONE GABRIELE M director, 10 percent owner, officer: No.. director, 10 percent owner, off..	Ordinary Shares	1,625,000	$0.06	$97,500

OKYO insider trading transactions

OKYO Pharma Limited
Latest News

Friday, 15 November 2024
09:00	MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV	accesswire.com
Wednesday, 30 October 2024
09:38	OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference	proactiveinvestors.com
Saturday, 26 October 2024
10:22	OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial - ICYMI	proactiveinvestors.com
Wednesday, 23 October 2024
09:40	OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial	proactiveinvestors.com
07:00	OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain	globenewswire.com
Wednesday, 16 October 2024
09:26	OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment	proactiveinvestors.com
Tuesday, 27 August 2024
08:43	OKYO Pharma secures key US patent for dry eye disease therapy	proactiveinvestors.com
Friday, 23 August 2024
09:00	OKYO Pharma CEO Interview to Air on Bloomberg TV	globenewswire.com
09:00	OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV	accesswire.com
07:00	OKYO Pharma Announces Chairman Acquires Shares	globenewswire.com
Wednesday, 21 August 2024
08:35	OKYO Pharma chairman acquires more shares in the company	proactiveinvestors.com
07:00	OKYO Pharma Announces Chairman Acquires Shares	globenewswire.com
Thursday, 15 August 2024
12:13	OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference	globenewswire.com
Tuesday, 6 August 2024
08:40	OKYO Pharma lands European patent protection for lead asset	proactiveinvestors.co.uk
07:00	OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use	globenewswire.com
Thursday, 11 July 2024
08:41	OKYO Pharma dry eye disease trial to get underway in the third quarter	proactiveinvestors.com
07:00	OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101	globenewswire.com
Wednesday, 10 July 2024
09:10	OKYO Pharma shares encouraging dry eye data	proactiveinvestors.com
07:00	OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease	globenewswire.com
Tuesday, 30 April 2024
07:00	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)	globenewswire.com
Tuesday, 9 April 2024
08:39	OKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader event	Proactive Investors
Friday, 22 March 2024
08:52	OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms	Proactive Investors
Thursday, 21 March 2024
09:23	OKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye disease	Proactive Investors
Wednesday, 20 March 2024
08:55	OKYO Pharma to release Phase 2 dry eye disease trial results on Friday	Proactive Investors
Friday, 9 February 2024
08:47	OKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trial	Proactive Investors
Wednesday, 31 January 2024
09:23	OKYO Pharma appoints leading ophthalmologists to its Scientific Advisory Board	Proactive Investors
Monday, 8 January 2024
09:56	OKYO Pharma reports 'statistical significance' achieved in Phase 2 trial of OK-101 in dry eye disease	Proactive Investors
Friday, 5 January 2024
09:30	OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024	GlobeNewsWire
Monday, 4 December 2023
08:17	OKYO Pharma on track as last patient enrolled in trial to treat dry eye disease completes final protocol visit	Proactive Investors
Monday, 9 October 2023
08:20	OKYO Pharma files IND application OK-101 to treat Neuropathic Corneal Pain	Proactive Investors

Ideas & Opinions

Seeking Alpha 21 May 2022

U.S. IPO Weekly Recap: 1 Small IPO And 1 Direct Listing Begin Trading

Frequently Asked Questions (FAQ)

What's the price of OKYO Pharma Limited stock today?

One share of OKYO Pharma Limited stock can currently be purchased for approximately $2.33.
When is OKYO Pharma Limited's next earnings date?

Unfortunately, OKYO Pharma Limited's (OKYO) next earnings date is currently unknown.
Does OKYO Pharma Limited pay dividends?

No, OKYO Pharma Limited does not pay dividends.
How much money does OKYO Pharma Limited make?

OKYO Pharma Limited has a market capitalization of 36.25M.
What is OKYO Pharma Limited's stock symbol?

OKYO Pharma Limited is traded on the NASDAQ under the ticker symbol "OKYO".
What is OKYO Pharma Limited's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of OKYO Pharma Limited?

Shares of OKYO Pharma Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does OKYO Pharma Limited have?

As Jul 2024, OKYO Pharma Limited employs 8 workers.
When OKYO Pharma Limited went public?

OKYO Pharma Limited is publicly traded company for more then 3 years since IPO on 17 May 2022.
What is OKYO Pharma Limited's official website?

The official website for OKYO Pharma Limited is okyopharma.com.
How can i contact OKYO Pharma Limited?

OKYO Pharma Limited can be reached via phone at +44 20 7495 2379.

OKYO Pharma Limited

okyopharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

+44 20 7495 2379

55 Park Lane
London, W1K 1NA

CIK: 0001849296
ISIN: US6793451088
CUSIP: 679345108